Y-mabs resubmits cancer drug for marketing approval in the US
After several years’ delay, Y-mabs has now filed another marketing application for cancer drug candidate with the US health authority after the first was rejected in 2020.
by christian bundgaard, translated by daniel pedersen
Danish-American biotech firm Y-mabs has announced it has resubmitted a Biologics License Application (BLA) for its delayed cancer drug candidate, omburtamab, with the US health authority, according to a company press release on Thursday last week.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.